Program
carbidopa, levodopa drug combination
Also written as “IPX066”, “Sinemet®” and “Levodopa-Carbidopa Intestinal Gel (LCIG)”.
Its studies are mostly in Parkinson Disease · Dyskinesias, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amneal Pharmaceuticals | 60 open or running | phase 3since Apr 3, 2009 | Mar 24, 2009 | none ahead |
| AbbVie | 40 open or running | phase 4since Aug 30, 2005 | Aug 30, 2005 | none ahead |
| Orion Corporation, Orion Pharma | 40 open or running | phase 2since Nov 19, 2007 | Nov 19, 2007 | none ahead |
| UCB | 20 open or running | phase 3since Aug 29, 2005 | Aug 29, 2005 | none ahead |
| Hong Kong WD Pharmaceutical | 10 open or running | phase 1since Nov 26, 2018 | Nov 26, 2018 | none ahead |
| Tanabe Pharma | 10 open or running | phase 1since Jun 22, 2015 | Jun 22, 2015 | none ahead |
Also a collaborator on its studies: TFS Trial Form Support and Abbott Japan.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Aug 29, 2005.
- Apr 15, 2008Phase 3 study in Parkinson DiseaseAbbVie · NCT00660673 · 262 enrolled · United States, Australia, Canada and more
- Mar 24, 2009Amneal Pharmaceuticals’ first study: phase 2 study in Parkinson DiseaseNew to Amneal PharmaceuticalsAmneal Pharmaceuticals · NCT00869791 · 27 enrolled · United States
- Apr 3, 2009Phase 3 study in Parkinson DiseaseAmneal Pharmaceuticals · NCT00880620 · 381 enrolled · United States, Canada, Estonia and more
- Sep 10, 2009Phase 3 study in Parkinson DiseaseAmneal Pharmaceuticals · NCT00974974 · 471 enrolled · United States, Canada, France and more
- Mar 25, 2010Phase 3 study in Parkinson DiseaseAmneal Pharmaceuticals · NCT01096186 · 617 enrolled · United States, Canada, Estonia and more
- May 24, 2010Phase 3 study in Parkinson DiseaseAmneal Pharmaceuticals · NCT01130493 · 110 enrolled · United States, France, Germany and more
- Aug 4, 2011Phase 3 study in Parkinson DiseaseAmneal Pharmaceuticals · NCT01411137 · 43 enrolled · United States
- Sep 26, 2011Phase 2 study in DyskinesiasAbbVie · NCT01479127 · 8 enrolled
- Dec 2, 2014Phase 1 study in Parkinson DiseaseOrion Corporation, Orion Pharma · NCT02312232 · 20 enrolled · Finland
- Jun 10, 2015Phase 1 study in Parkinson DiseaseOrion Corporation, Orion Pharma · NCT02554734 · 15 enrolled · Finland
- Jun 22, 2015Tanabe Pharma’s first study: phase 1 study in Parkinson DiseaseNew to Tanabe PharmaTanabe Pharma · NCT02486432 · 6 enrolled
- Jun 10, 2016Phase 3 study in Parkinson DiseaseAbbVie · NCT02799381 · 63 enrolled · United States, Finland, Greece and more
- Apr 12, 2017Phase 1 study in Parkinson DiseaseOrion Corporation, Orion Pharma · NCT03140956 · 20 enrolled · Finland
- Nov 26, 2018Hong Kong WD Pharmaceutical’s first study: phase 1 study in Healthy VolunteersNew to Hong Kong WD PharmaceuticalHong Kong WD Pharmaceutical · NCT03761004 · 8 enrolled · Canada
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT03761004Healthy Volunteers · Canada | 1 | Completed | Hong Kong WD Pharmaceutical | Sep 5, 2019 | 8 |
| NCT03140956Parkinson Disease · Finland | 1 | Completed | Orion Corporation, Orion Pharma | Jul 3, 2017 | 20 |
| NCT02799381Parkinson Disease · United States, Finland, Greece and more | 3 | Completed | AbbVie | Sep 19, 2019 | 63 |
| NCT02486432Parkinson Disease | 1 | Completed | Tanabe Pharma | Apr 2015 | 6 |
| NCT02554734Parkinson Disease · Finland | 1 | Completed | Orion Corporation, Orion Pharma | Nov 2015 | 15 |
| NCT02312232Parkinson Disease · Finland | 1 | Completed | Orion Corporation, Orion Pharma | Feb 2015 | 20 |
| NCT01479127Dyskinesias | 2 | Completed | AbbVie | Jul 2012 | 8 |
| NCT01411137Parkinson Disease · United States | 3 | Completed | Amneal Pharmaceuticals | Mar 2013 | 43 |
| NCT01130493Parkinson Disease · United States, France, Germany and more | 3 | Completed | Amneal Pharmaceuticals | Jan 2012 | 110 |
| NCT01096186Parkinson Disease · United States, Canada, Estonia and more | 3 | Completed | Amneal Pharmaceuticals | Oct 2011 | 617 |
| NCT00974974Parkinson Disease · United States, Canada, France and more | 3 | Completed | Amneal Pharmaceuticals | Jan 2011 | 471 |
| NCT00880620Parkinson Disease · United States, Canada, Estonia and more | 3 | Completed | Amneal Pharmaceuticals | Oct 2010 | 381 |
| NCT00869791Parkinson Disease · United States | 2 | Completed | Amneal Pharmaceuticals | Jun 2009 | 27 |
| NCT00660673Parkinson Disease · United States, Australia, Canada and more | 3 | Completed | AbbVie | Nov 30, 2021 | 262 |
| NCT00562198Parkinson Disease · Finland | 2 | Terminated | Orion Corporation, Orion Pharma | Feb 2008 | 16 |
| NCT00141518Advanced Idiopathic Parkinson's Disease | 4 | Completed | AbbVie | Mar 2011 | 77 |
| NCT00139880Parkinson Disease · United States | 3 | Completed | UCB | Aug 2005 | |
| NCT00139867Parkinson Disease · United States | 3 | Completed | UCB | May 2004 |
How it is read
Names in the registry
- “IPX066”, 4 entries
- “Sinemet®”, 3 entries
- “Levodopa-Carbidopa Intestinal Gel (LCIG)”, 2 entries
- “levodopa, carbidopa, ODM-104”, 2 entries
- “HRG2010 Capsule, Sinemet®, Madopar®”, 1 entry
Conditions, from the studies’ own filings
- Parkinson Disease, 24 studies
- Dyskinesias, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.